Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
Dr. Michael Aitkenhead is a qualified physician with more than 12 years' experience in the healthcare industry, including five years in clinical medicine and seven years in biopharmaceutical equity research. He was formerly a European pharmaceuticals analyst at the Royal Bank of Scotland in London, and prior to this was a European biotechnology analyst with Piper Jaffray. Aitkenhead received his medical degree from the University of Otago, New Zealand, and subsequently completed a master's degree in business administration at Judge Business School, University of Cambridge.
New Biotech Names with Excellent Prospects: Michael Aitkenhead (6/13/13) In a marketplace as diverse as biotech, picking the best and brightest can stymie even the savviest investor. Senior biotechnology analyst and physician Michael Aitkenhead of Edison Investment Research has done meticulous research on both the science and unmet needs to reveal the growth potential of biotechs with vastly different stories, disease indications and markets. In this interview with The Life Sciences Report, Aitkenhead details his thesis on three names, each with the ability to return large multiples on original investment.
"CYTR's preclinical data for aldoxorubicin has been very supportive, and its phase 1b/2 trial has shown quite promising, albeit early stage, efficacy." (6/13/13) CytRx Corp. - The Life Sciences Report Interview with Michael Aikenhead More >
"FDA agreement on CYRT's aldoxorubicin pivotal phase 3 study in second-line soft tissue sarcoma paves the way for trial initiation in Q3/13." (4/25/13) CytRx Corp. - Michael Aitkenhead, Edison Investment Research More >
"I expect results from NBS' Phase 2 PreSERVE-AMI trial in Q4/14; that will be proof of concept for this approach." (9/10/14) NeoStem Inc. - The Life Sciences Report Interview with Vernon Bernardino More >